language_icon
EN
HI

Dr Reddy's Laboratories. Share price

DRREDDY

1274

16.40 (-1.27%)
NSE
BSE
Last updated on 2 Jun, 2026 | 15:58 IST
Today's High

1284.70

Today's Low

1264.10

52 Week Low

1148.40

52 Week High

1379.70

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Dr Reddy's Laboratories Chart

Dr Reddy's Laboratories. Share Key Metrics

Volume
20.22 L
Market Cap
106333.52 CR
LTQ@LTP
10@1274.00
ATP
1272.83
Var Margin
12.86 %
Circuit Range
1161.4-1419.4
Delivery %
49.59 %
Value
257.34 CR
ASM/GSM
No
Market Lot
1

Summary

Dr Reddy's Laboratories. share price is ₹1274 as of 3 Jun, 2026. The stock Dr Reddy's Laboratories. intraday movement has stayed between ₹1264.10 and ₹1284.70, while on a 52-week basis,Dr Reddy's Laboratories. price 52 week high is ₹1379.70 & its 52 week low is ₹1148.40.
In terms of trading activity, Dr Reddy's Laboratories. has recorded a volume of 2021793 shares, The Dr Reddy's Laboratories. has a market cap of ₹834643020 CR. The stock’s Average Traded Price (ATP) stands at ₹1272.83, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 10 @ ₹1274.00.
Dr Reddy's Laboratories. operates within a circuit range of ₹1161.40 – ₹1419.40, with a Value of ₹257.34 CR. The Delivery Percentage for the day is 49.59%. Additionally, Dr Reddy's Laboratories. currently falls under the No framework, and trades with a market lot size of 1.

Dr Reddy's Laboratories. Fundamentals

View More
P/E Ratio

25.65

P/B Ratio

2.84

Div. Yield

0.62

Sector P/E

69.94

Sector P/B

2.97

Sec. Div. Yield

0.55

Dr Reddy's Laboratories. Resistance and Support

Pivot 1298.27

Resistance

First Resistance

1311.74

Second Resistance

1333.07

Third Resistance

1346.54

Support

First Support

1276.94

Second Support

1263.47

Third Support

1242.14

Dr Reddy's Laboratories. Futures & Options

link_white_icon

Dr Reddy's Laboratories. Option Chain

View Price, OI, Greeks & More...
View All

30JUN26

1281.00

-14.50 (1.12%)

28JUL26

1284.20

-6.30 (0.49%)

25AUG26

1295.90

0.00 (0.00%)

DRREDDY|30JUN26 CE 1270.00

38.00

-11.3 (-22.92%)

DRREDDY|30JUN26 PE 1280.00

30.8

4.8 (18.46%)

Dr Reddy's Laboratories. Shareholding Pattern

View More
  • 2016-17
  • 2017-18
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

26.63%

Mutual Fund

13.19%

Insurance

14.64%

Foreign Institutional Investors

21.14%

Domestic Institutional Investors

2.89%

Retail

9.57%

Others

11.94%

Total Promoters
MAR '26
26.63%

Dr Reddy's Laboratories. Corporate Actions

DateAgenda
2026-05-12Audited Results
2026-01-21Quarterly Results
2025-10-24Quarterly Results
2025-07-23Quarterly Results
2025-05-09Audited Results
2025-01-23Quarterly Results

Dr Reddy's Laboratories. News

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Dr. Reddy's Laboratories management is scheduled to participate in an in-person group investor meeting with Bank of America on June 5, 2026, from 8:00 to 9:00 IST in Hyderabad. This meet is for interaction with institutional investor groups.
Jun 01 2026 15:37:56

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Dr. Reddy's Laboratories has filed the transcript of its earnings call for Q4 FY26, which took place on May 12, 2026. This provides investors access to detailed discussions about the company's financial performance and outlook.
May 18 2026 21:29:57

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Dr. Reddy's Laboratories launched its generic Semaglutide Injection in Canada, making it the first company to receive Health Canada approval for this diabetes treatment in a G7 country. This expands its GLP-1 therapies portfolio into a key new market.
May 16 2026 00:16:25

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Dr. Reddy's Laboratories made available the audio recording of its earnings call held on May 12, 2026. The call reviewed the company's performance for the quarter ended March 31, 2026, providing insights into its latest financial results.
May 12 2026 23:28:44

Dr Reddys Laboratories Ltd - 500124 - Corporate Action-Board to consider Dividend

Dr. Reddy's Laboratories recommended a final dividend of ₹8 per equity share for FY26. The dividend is subject to shareholder approval at the AGM, with a record date of July 10, 2026.
May 12 2026 17:15:22

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Change in Management

Dr. Reddy's Laboratories has elevated Mr. Sandeep Khandelwal, Global Generics India Head, to Senior Management Personnel, inducting him into the Management Council. Khandelwal significantly grew the India business from Rs.2,300 crore to Rs.7,000 crore.
May 12 2026 17:02:20

Dr Reddys Laboratories Ltd - 500124 - Fixing Of Record Date As July 10, 2026 For The Purpose Of Payment Of Final Dividend For FY 2025-26

Dr. Reddy's Laboratories fixed July 10, 2026, as the record date for its final dividend of ₹8.00 per equity share for FY26. Payment is subject to shareholder approval at the upcoming AGM.
May 12 2026 16:54:51

Dr Reddys Laboratories Ltd - 500124 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 12, 2026

Dr. Reddy's Laboratories reported Q4 FY26 cons. revenue of ₹7,516 cr (down 11.6% YoY) and net profit of ₹220 cr (down 86% YoY). The Board also recommended a final dividend of ₹8 per equity share for FY26.
May 12 2026 16:38:35

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Dr. Reddy's Laboratories management is scheduled to participate in investor group meetings with HSBC in Mumbai from May 14-15, 2026, and with Bank of America in Singapore from May 18-19, 2026. These meetings are part of routine investor engagement.
May 11 2026 21:47:08
Read More

Dr Reddy's Laboratories. Management

NamePosition
K Randhir SinghCompany Secretary, Compliance Officer and Head-CSR
K Satish ReddyChairman
View More

Dr Reddy's Laboratories. FAQs

The Buying Price of Dr Reddy's Laboratories. share is 1274 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Dr Reddy's Laboratories. stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Dr Reddy's Laboratories., choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Dr Reddy's Laboratories. shares is 25.65. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Dr Reddy's Laboratories. shares is 2.84. Useful to assess the stock's value relative to its book value.

To assess Dr Reddy's Laboratories.’s valuation compare Sector P/E, P/B which are 69.94 & 2.97 with sector averages, along with growth rates and financial metrics.

The Market Cap of Dr Reddy's Laboratories. is 106333.52 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Dr Reddy's Laboratories. share price is 1379.70 & 1148.40. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Dr Reddy's Laboratories. belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost